Better prognostic biomarkers are urgently needed to identify patients with early-stage cutaneous melanoma who will progress to aggressive disease. In the past grant period, Project II successfully developed the quantitative real-time RT-PCR assay to detect micrometastases not identified by histopathologic assessment of sentinel lymph nodes (SLN). Project II then adapted this assay for analysis of paraffin-embedded SLN specimens, and incorporated this assay as a stratification factor in the international phase III trial (MSLT-II, Project III, and Core C). In the present proposal, Project II will develop and validate clinically relevant prognostic biomarkers by undertaking genomic/epigenomic/mRNA analyses of primary tumor tissue, metastatic tumor tissue, and blood from melanoma patients accrued in the past grant period. The objective is to develop a molecular model that combines tissue-based assays and blood-based serial assays for diagnosis and prognosis. The objectives are further defined in three aims:
Aim I, Assessment of prognostic DNA biomarkers in primary melanomas of patients who have undergone SLN biopsy for melanoma.
Aim II, Identification of prognostic RNA and DNA biomarkers in nodal and distant metastases of patients who have undergone SLN biopsy for melanoma.
Aim III, Identification and assessment of prognostic circulating DNA and circulating tumor-cell biomarkers for detection of melanoma recurrence after SLN biopsy. These three Aims will take advantage of several unique resources: the clinical specimens with clinical follow-up records for patients in the two ongoing international phase III trials (MSLT-I and MSLT-II, Project Ill) and the extensive independent specimen bank/clinical database at the JWCI melanoma center. Results of these molecular biomarker studies will improve treatment selection for patients with early-stage melanoma and increase early detection of recurrent metastatic melanoma during SLN biopsy postoperative follow-up. This approach will help improve melanoma patient management and staging, especially those of early aggressive disease.

Public Health Relevance

Systemic metastasis of malignant cutaneous melanoma has a very poor prognosis which may be alleviated by early diagnosis and early detection of occult metastasis. Our objective in this proposal is to improve the molecular assessment of melanoma by developing and validating a panel of clinically relevant RNA and DNA prognostic biomarkers through assessment of primary tumors and lymph node metastasis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA029605-32
Application #
8544987
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
32
Fiscal Year
2013
Total Cost
$641,311
Indirect Cost
$428,342
Name
John Wayne Cancer Institute
Department
Type
DUNS #
556074458
City
Santa Monica
State
CA
Country
United States
Zip Code
90404
Jones, Maris S; Lee, Jihey; Stern, Stacey L et al. (2017) Is Pregnancy-Associated Melanoma Associated with Adverse Outcomes? J Am Coll Surg 225:149-158
Faries, Mark B; Thompson, John F; Cochran, Alistair J et al. (2017) Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 376:2211-2222
Ozao-Choy, Junko; Nelson, Daniel W; Hiles, Jason et al. (2017) The prognostic importance of scalp location in primary head and neck melanoma. J Surg Oncol 116:337-343
Karakousis, Giorgos; Gimotty, Phyllis A; Bartlett, Edmund K et al. (2017) Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis. Ann Surg Oncol 24:952-959
Jones, Maris S; Torisu-Itakura, Hitoe; Flaherty, Devin C et al. (2016) Second Primary Melanoma: Risk Factors, Histopathologic Features, Survival, and Implications for Follow-Up. Am Surg 82:1009-1013
Faries, Mark B (2016) Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology. Crit Rev Oncog 21:65-73
Ono, Shigeshi; Oyama, Takashi; Lam, Stella et al. (2015) A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget 6:7053-64
Wang, Jinhua; Huang, Sharon K; Marzese, Diego M et al. (2015) Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Dermatol 135:532-541
Cochran, Alistair J; Huang, Rong-Rong; Su, Albert et al. (2015) Is sentinel node susceptibility to metastases related to nodal immune modulation? Cancer J 21:39-46
Marzese, Diego M; Huang, Sharon K; Hoon, Dave S B (2015) In Situ Sodium Bisulfite Modification of Genomic DNA from Microdissected Melanoma Paraffin-Embedded Archival Tissues. Methods Mol Biol :

Showing the most recent 10 out of 256 publications